Short answer
Pacira BioSciences, Inc. (PCRX) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure). Ninth Circuit reversal reinstates Pacira’s royalty obligation for EXPAREL manufactured using the 200-liter process.
Pacira BioSciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Ninth Circuit reversal reinstates Pacira’s royalty obligation for EXPAREL manufactured using the 200-liter process
- District Court must recalculate RDF’s pre-judgment interest owed on 45-liter EXPAREL royalties
- Prior $28.3 million cash recovery from RDF now subject to litigation-related uncertainty
- Pacira evaluating legal options, with final financial impact currently unpredictable
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pacira BioSciences, Inc. 8-K filings
Get the next PCRX 8-K as it lands
Follow PCRX for push alerts, or ask the research agent what this filing means.